Works cited by this work

24 works

Work: Catumaxomab: First Approval

1. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

   Peter Ruf, Michael Kluge, Michael Jäger +7

   Article20103 citations

   ABIABI:AkademIndex/openalex/2026.other.913630

2. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

   Peter Ruf, Horst Lindhofer

   Article20013 citations

   ABIABI:AkademIndex/openalex/2026.other.913633

3. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

   Alexander Burges, Pauline Wimberger, Carolin Kümper +15

   Article20073 citations

   ABIABI:AkademIndex/openalex/2026.other.913648

4. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

   Reinhard Zeidler, Josef Mysliwietz, M Csanády +5

   Article20002 citations

   ABIABI:AkademIndex/openalex/2026.other.913701

5. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

   Peter Ruf, Olivier Gires, Michael Jäger +3

   Article20072 citations

   ABIABI:AkademIndex/openalex/2026.other.913704

6. Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

   Michael Jäger, A. Schoberth, Peter Ruf +8

   Article20112 citations

   ABIABI:AkademIndex/openalex/2026.other.913705

7. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

   M. M. Heiss, P. Murawa, P. Koralewski +17

   Article20102 citations

   ABIABI:AkademIndex/openalex/2026.other.913710

8. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

   Marion Ott, Frederik Marmé, Gerhard Moldenhauer +6

   Article20112 citations

   ABIABI:AkademIndex/openalex/2026.other.913711

9. Catumaxomab

   James E. Frampton

   Review articleNanoparticle-Based Drug DeliveryDrugs20121 citations

   ABIABI:AkademIndex/openalex/2012.review-article.000001

10. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913805

11. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913806

12. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913807

13. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913808

14. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913809

15. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913810

16. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913811

17. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913812

18. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913813

19. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913814

20. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913815

21. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913816

22. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913817

23. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913818

24. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.913819